Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

$465.73 -2.40 (-0.51%)

(As of 12/2/2024 ET)

Vertex Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 29 Analyst Ratings

Sell
3

Hold
8

Buy
18

Based on 29 Wall Street analysts who have issued ratings for Vertex Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 29 analysts, 3 have given a sell rating, 8 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for VRTX.

Consensus Price Target

$504.38
8.30% Upside

According to the 29 analysts' twelve-month price targets for Vertex Pharmaceuticals, the average price target is $504.38. The highest price target for VRTX is $600.00, while the lowest price target for VRTX is $325.00. The average price target represents a forecasted upside of 8.30% from the current price of $465.73.

Get the Latest News and Ratings for VRTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors.

VRTX Analyst Ratings Over Time

Type	Current Forecast 12/4/23 to 12/3/24	1 Month Ago 11/4/23 to 11/3/24	3 Months Ago 9/5/23 to 9/4/24	1 Year Ago 12/4/22 to 12/4/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	17 Buy rating(s)	16 Buy rating(s)	12 Buy rating(s)
Hold	8 Hold rating(s)	9 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$504.38	$492.50	$485.91	$376.13
Forecasted Upside	8.30% Upside	4.54% Upside	1.53% Upside	7.27% Upside
Consensus Rating	Moderate Buy	Hold	Moderate Buy	Moderate Buy

My most important prediction yet (Ad)

One year ago at this time, I was gearing up to do something I’d never done before… After years of working behind the scenes, helping Tom Busby and teaching traders all about the markets, I was about ready to jump in front of a camera. Why? Because my research and years of expertise were showing me a phenomenon that people NEEDED to know about. That gold was setting up to go on a historic run that I called the “2024 Gold Supercycle.” I went LIVE on December 7, 2023, and made my bold prediction — staking 20+ years of a reputation on this one public prognostication. And the rest, as they say, is history… Gold went on to have its best year since 1979 — almost half a century! I’m going to tell you all about it on Wednesday, December 4th @ 1:00 PM ET, 362 days after I first made my prediction on gold.

Go here and finish your registration to receive your access link

VRTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Vertex Pharmaceuticals Stock vs. The Competition

Type	Vertex Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.55	2.81	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	8.30% Upside	25,916.81% Upside	7.05% Upside
News Sentiment Rating	Very Positive News See Recent VRTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/14/2024	Citigroup 3 of 5 stars		Initiated Coverage	Buy	$575.00	+16.25%
11/6/2024	Canaccord Genuity Group 1 of 5 stars		Boost Target	Sell ➝ Sell	$361.00 ➝ $408.00	-17.00%
11/5/2024	Scotiabank 5 of 5 stars	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Perform ➝ Sector Perform	$480.00 ➝ $486.00	-2.78%
11/5/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Bristow Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$562.00 ➝ $586.00	+17.77%
11/5/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Perform ➝ Sector Perform	$437.00 ➝ $451.00	-8.68%
11/5/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$480.00 ➝ $480.00	-2.81%
Get the Latest News and Ratings for VRTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
11/5/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$510.00 ➝ $503.00	+2.95%
11/5/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$473.00 ➝ $476.00	-0.83%
10/30/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$550.00 ➝ $540.00	+13.86%
10/21/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$600.00 ➝ $600.00	+24.22%
10/14/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$550.00 ➝ $541.00	+12.03%
10/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
8/5/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$508.00 ➝ $550.00	+16.17%
8/5/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Wang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$472.00 ➝ $509.00	+2.94%
8/2/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$450.00 ➝ $558.00	+13.08%
8/2/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$500.00 ➝ $535.00	+7.40%
7/26/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
7/23/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$450.00 ➝ $500.00	+1.60%
6/27/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Chesney Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$545.00	+14.98%
6/24/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$540.00 ➝ $555.00	+18.41%
6/17/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$465.00 ➝ $550.00	+15.48%
5/31/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$480.00 ➝ $500.00	+11.63%
4/11/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	In-Line ➝ Outperform	$438.00	+10.17%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$515.00	+23.24%
2/6/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
2/2/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
1/31/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$325.00	-25.27%
1/31/2024	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
11/22/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold ➝ Hold	$373.00	+5.81%
6/26/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
5/25/2023	Westpark Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
2/8/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$374.00 ➝ $365.00	+18.30%
2/8/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$374.00 ➝ $365.00	+18.30%
12/19/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$340.00	+11.55%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:28 PM ET.

Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, December 1, 2024. Please send any questions or comments about these Vertex Pharmaceuticals pros and cons to contact@marketbeat.com.

Vertex Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Vertex Pharmaceuticals Incorporated:

Vertex Pharmaceuticals Incorporated recently reported earnings per share (EPS) of $4.38, exceeding analyst expectations of $3.61, indicating strong financial performance and effective management.
The company's revenue increased by 11.6% year-over-year, reaching $2.77 billion, showcasing its growth potential and ability to expand its market presence.
With a current stock price of $468.13, analysts have set an average target price of $504.38, suggesting potential upside for investors looking for capital appreciation.
Vertex Pharmaceuticals Incorporated has received a consensus rating of "Moderate Buy" from analysts, with 18 buy ratings, indicating strong market confidence in the company's future performance.
The firm has a low debt-to-equity ratio of 0.01, which suggests financial stability and a lower risk profile, making it an attractive option for risk-averse investors.

Vertex Pharmaceuticals
Bear Case

Investors should be bearish about investing in Vertex Pharmaceuticals Incorporated for these reasons:

Despite recent growth, the company has a negative net margin of 4.52%, which may raise concerns about profitability and operational efficiency.
Analysts forecast a negative EPS of -1.83 for the current year, indicating potential challenges ahead and uncertainty regarding future earnings.
Three analysts have issued sell ratings for Vertex Pharmaceuticals Incorporated, suggesting that some market experts are cautious about the stock's performance.
The stock has a high price-to-earnings ratio of -235.24, which can indicate overvaluation and may deter value-focused investors.
Insider selling activity has been noted, with significant shares sold by executives, which could signal a lack of confidence in the company's short-term prospects.

VRTX Forecast - Frequently Asked Questions

: According to the research reports of 29 Wall Street equities research analysts, the average twelve-month stock price forecast for Vertex Pharmaceuticals is $504.38, with a high forecast of $600.00 and a low forecast of $325.00.
: 29 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 3 sell ratings, 8 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VRTX shares.
: According to analysts, Vertex Pharmaceuticals's stock has a predicted upside of 8.30% based on their 12-month stock forecasts.
: Over the previous 90 days, Vertex Pharmaceuticals's stock had 1 upgrade by analysts.
: Vertex Pharmaceuticals has been rated by research analysts at Bank of America, Canaccord Genuity Group, Cantor Fitzgerald, Citigroup, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer, Raymond James, Royal Bank of Canada, Scotiabank, and UBS Group in the past 90 days.
: Analysts like Vertex Pharmaceuticals less than other "medical" companies. The consensus rating score for Vertex Pharmaceuticals is 2.55 while the average consensus rating score for "medical" companies is 2.81. Learn more on how VRTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

My most important prediction yet (Ad)

Go here and finish your registration to receive your access link

This page (NASDAQ:VRTX) was last updated on 12/3/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target